NCT03040635View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 22, 2017

Primary Completion Date

October 2, 2017

Study Completion Date

October 2, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

Risdiplam

Single oral doses of Risdiplam will be administered on Day 1.

DRUG

Placebo

Single oral doses of Risdiplam matching placebo will be administered on Day 1.

Trial Locations (1)

92845

Collaborative Neuroscience Network, Inc., Garden Grove

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03040635 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants | Biotech Hunter | Biotech Hunter